SurModics (SRDX) Reports Q1 EPS of $0.12, Revenues Beat; Raises FY19 EPS/Revenue Mid-Point Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Surmodics Reports First Quarter Fiscal 2019 Results
January 30, 2019 4:05 PM ESTUpdates Fiscal 2019 Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 first quarter ended December 31, 2018 and updated its financial outlook for fiscal 2019.
Summary of First Quarter Fiscal 2019 Highlights
Revenue of $22.2 million, an increase of 31% year-over-year GAAP EPS of $0.09, non-GAAP EPS of $0.12 Updating fiscal 2019 revenue and EPS guidance Initial patient... More